-
公开(公告)号:JP2595931B2
公开(公告)日:1997-04-02
申请号:JP11948392
申请日:1992-03-26
IPC分类号: A61K31/40 , A61K31/44 , A61K31/4427 , A61P7/02 , C07D207/02 , C07D207/46 , C07D207/50 , C07D401/06
-
公开(公告)号:JPH07149643A
公开(公告)日:1995-06-13
申请号:JP22385594
申请日:1994-09-20
申请人: TANABE SEIYAKU CO
发明人: IWASAKI TAMEO , NISHITANI TAKASHI , OTANI AKIO , INAMASU MASANORI
IPC分类号: C07D401/06 , A61K31/40 , A61K31/44 , A61K31/4427 , A61K31/535 , A61P7/02 , A61P9/00 , A61P9/10 , C07D207/02 , C07D207/46 , C07D207/50
摘要: PURPOSE:To obtain an antithrombotic medicine exhibiting excellent antithrombotic action and capable of using as a medicine for preventing and treating vascular diseases such as cardiac infarction and diabetic complication. CONSTITUTION:This antithrombotic medicine contains a 2,5-pyrrolidine-dione derivative of the formula (ring A is a trialkoxyphenyl; R is a substitutive alkyl, a substitutive alkoxy, a substitutive amino or pyridinylcarbonyl) or its pharmacologically permissible salt, e.g. (3E,4E)-1-methyl-3-benzylidene-4-(3,4,5- trimethoxybenzylidene)-2,5-pyrrolidinedione as an active ingredient. The compound has excellent PA activity promoting action and PAT-1 activity inhibiting action and exhibits excellent antithrombotic action even in either of oral administration and parental administration. The dose of the compound is preferably 0.5-50mg/kg.day in oral administration and preferably 0.05-5mg/kg.day in parental administration. The antithrombotic medicine can be used also as a medicine for preventing reobstruction after percutaneous coronary artery forming operation or after thrombolytic therapy or a medicine for preventing and treating arteriosclerosis.
-
公开(公告)号:JPH0665134A
公开(公告)日:1994-03-08
申请号:JP21767192
申请日:1992-08-17
申请人: DAICEL CHEM
发明人: TODA FUMIO
IPC分类号: C07C49/747 , C07D207/02 , C07D209/66 , C07D307/92 , C07D335/08
摘要: PURPOSE:To obtain an optically active compound, useful as a new optical record ing material or a reagent, etc., for optical resolution and having a new succinimide skeleton etc. CONSTITUTION:The objective optically active compound is expressed by formula I [X is =CH2, O, S or =NR (R is H or alkyl); A is aromatic group; Y is H or substituent group], e.g. a compound expressed by formula II. This optically active compound expressed by formula I is obtained by irradiating a new optically active precursor expressed by formula III with light. This optically active precursor expressed by formula III is obtained by adding acetic acid or an optically active compound to a racemic modification of a compound having the structure expressed by formula III.
-
公开(公告)号:JPH03178961A
公开(公告)日:1991-08-02
申请号:JP24666390
申请日:1990-09-17
发明人: IWAMOTO OSAMU , HARA TAIZO , SUGIYAMA HARUHIKO
IPC分类号: C07D403/06 , C07D207/02 , C07D405/06 , C07D409/06 , C07D413/06 , C07D417/06 , C07D421/06 , C08F20/34 , C08F20/52 , C08F36/02 , C08F36/04 , C08F220/36 , C08F220/60 , C09K9/02
摘要: NEW MATERIAL:A fulgimide derivative shown by formula I [R , R and R are H, halogen alkyl, alkoxy, cycloalkyl, aryl, aralkyl or aryloxy or R and R are mutually bonded to form cyclic group such as adamanthyl or norbornyl; R is group shown by formula II, formula II, formula VI, etc., (R ' is H, halogen, alkyl, etc.; R ' to R ' are H, alkyl, alkoxy etc.; S is O, S, etc.); X is bifunctional organic residue; R is group shown by formula V, etc., (R' is H or alkyl)]. EXAMPLE:N-(4-Acryloyloxyphenyl)-2-[(E)-1-(2,5-dimehyl-3-furyl)ethylide ne]-3- isopropylidenesuccinimide. USE:Having photochromic action and useful as a recording material, copying material, printing photosensitizer, etc. PREPARATION:For example, a compound shown by formula VI is reacted with a compound shown by formula VII to give a compound shown by formula I.
-
公开(公告)号:JPS62103058A
公开(公告)日:1987-05-13
申请号:JP17262786
申请日:1986-07-22
申请人: KOWA CO
发明人: FUJII SETSUO , HATTORI EIZO , HIRATA MITSUTERU , WATANABE KOICHIRO , OTA TOMIO , YOKOO NOBUO , NAGAKURA MASAHIKO
IPC分类号: C12N9/99 , A61K31/16 , A61K31/22 , A61K31/245 , A61K31/40 , A61K31/445 , A61K31/495 , A61K31/535 , A61P7/02 , A61P43/00 , C07C20060101 , C07C63/08 , C07C67/00 , C07C239/00 , C07C279/18 , C07D20060101 , C07D207/02 , C07D211/00 , C07D233/00 , C07D243/08 , C07D295/04 , C07D295/14 , C07D295/18
摘要: NEW MATERIAL:The compound of formula I [R1 and R2 are H or lower alkoxy; A is single bond, lower alkylene or lower alkenylene; R3 and R4 are lower alkyl or R3 and R4 together form lower alkylene; R5 is -X-(CO)n-Y (X is single bond, lower alkylene, etc.; n is 0 or 1; Y is H, cycloalkyl, aryl, etc.), etc.]. EXAMPLE:4-[4-( Carbamoylmethyl )piperidinocarbonylmethyl]phenyl 4-guanidino benzoate dihydrochloride. USE:It has the activity of proteolytic enzyme and is useful for the remedy of pancreatitis, thrombotic syndrome, etc. PREPARATION:The compound of formula I can be produced by carrying out dehydrative condensation of p-nitrobenzoic acid of formula II with the compound of formula III, reducing the resultant compound of formula IV to convert the nitro group to amino group and guanidinating the product.
-
公开(公告)号:JPS624385B2
公开(公告)日:1987-01-30
申请号:JP5062775
申请日:1975-04-25
申请人: HOECHST AG
IPC分类号: C07D207/04 , A61K20060101 , A61K31/125 , A61K31/18 , A61K31/33 , A61K31/395 , A61K31/397 , A61K31/40 , A61K31/4015 , A61K31/402 , A61K31/403 , A61K31/4035 , A61K31/445 , A61K31/45 , A61K31/635 , A61P7/10 , C07C20060101 , C07D20060101 , C07D205/04 , C07D205/10 , C07D207/02 , C07D207/06 , C07D207/08 , C07D207/10 , C07D207/18 , C07D207/20 , C07D207/32 , C07D207/327 , C07D207/40 , C07D207/404 , C07D207/44 , C07D207/452 , C07D209/00 , C07D209/44 , C07D209/48 , C07D209/52 , C07D209/94 , C07D211/04 , C07D211/14 , C07D211/18 , C07D211/30 , C07D211/32 , C07D211/34 , C07D211/38 , C07D211/70 , C07D211/88 , C07D265/32 , C07D265/33 , C07D295/00 , C07D295/02 , C07D295/04 , C07D295/08 , C07D295/10 , C07D295/116 , C07D295/12 , C07D295/14 , C07D295/155 , C07D295/18 , C07D295/192 , C07D317/00 , C07D403/10 , C07D405/10 , C07D407/10 , C07D413/10
摘要: 1504505 Sulphonamides HOECHST AG 25 April 1975 [25 April 1974 27 Dec 1974] 17337/75 Heading C2C The invention comprises novel compounds (I) (including salts thereof) in which R 1 and R 2 , which may be identical or different, each represents a hydrogen atom or an alkyl group having from 1 to 4 carbon atoms, and, if R 1 represents a hydrogen atom, R 2 may also represent an alkoxymethyl group having from 1 to 4 carbon atoms in the alkoxy radical, a phenoxymethyl group or a phenylthiomethyl group, R 3 represents a hydrogen atom, a straight or branched chain alkyl group having from 1 to 4 carbon atoms, a cycloalkyl group, having 5 or 6 ring members, one of which may be replaced by an oxygen or sulphur atom, a phenyl or benzyl group which may be substituted in the phenyl nucleus by one or more substituents selected from nitro groups, alkyl groups having from 1 to 3 carbon atoms, alkoxy groups having from 1 to 5 carbon atoms and halogen atoms, or represents a benzhydryl group or an alkanoyloxymethyl group having 2 to 4 carbon atoms in the alkanoyl part, X represents a halogen atom, a CF 3 or CCl 3 group, a straight or branched chain, saturated or unsaturated alkyl group having from 1 to 6 carbon atoms, a benzyl group which may be substituted in the phenyl nucleus by one or more substituents selected from halogen atoms, hydroxy and amino groups, and alkyl and alkoxy groups, or represents one of the groups -O-R 4 , -S-R 4 , SO-R 4 , SO 2 -R 4 and NR 4 R 5 , in which R 4 represents a phenyl group which may be substituted by one or more substituents selected from halogen atoms, CF 3 , OH and amino groups, alkyl and alkoxy groups having from 1 to 4 carbon atoms, and SO 2 NH 2 groups, or represents a straight or branched chain alkyl group having from 1 to 4 carbon atoms which may be substituted by a phenyl, pyridyl, furyl or thienyl group, and R 5 represents a hydrogen atom, a straight or branched chain alkyl group having from 1 to 4 carbon atoms, and the group NR 4 R 5 may represent a saturated, heterocyclic, 5- or 6-membered ring which may be interrupted by an O-, N- or S- atom, A represents a single bond, or an alkylene chain of 1 to 3 carbon atoms which may be unsaturated, interrupted by O-, N- or S-atoms or substituted by halogen atoms and/or substituted by alkyl, aralkyl, aryl groups or by mono-nuclear hetero-aromatic rings, or A represents an ortho-phenylene radical or the grouping in which Y represents a single bond or an alkylene group having from 1 to 4 carbon atoms, and R 6 and R 7 , which may be identical or different, each represents a hydrogen or halogen atom or an alkyl group having from 1 to 4 carbon atoms. They are made by standard methods. Pharmaceutical preparations having diuretic and saluretic action contain (I) as active ingredient. Administration is enterally or parenterally.
-
公开(公告)号:JPS585196B2
公开(公告)日:1983-01-29
申请号:JP11274379
申请日:1979-09-03
申请人: PFIZER
IPC分类号: C07D207/27 , A61K31/40 , A61K31/4015 , A61K31/5575 , A61K31/559 , A61P43/00 , C07C405/00 , C07D207/02 , C07D207/26 , C07D487/04
-
公开(公告)号:JPS5531147B2
公开(公告)日:1980-08-15
申请号:JP9458977
申请日:1977-08-06
IPC分类号: C07D207/27 , A61K31/40 , A61K31/4015 , A61K31/5575 , A61K31/559 , A61P43/00 , C07C405/00 , C07D207/02 , C07D207/26 , C07D487/04
-
公开(公告)号:JPS5555161A
公开(公告)日:1980-04-22
申请号:JP11274379
申请日:1979-09-03
申请人: PFIZER
IPC分类号: C07D207/27 , A61K31/40 , A61K31/4015 , A61K31/5575 , A61K31/559 , A61P43/00 , C07C405/00 , C07D207/02 , C07D207/26 , C07D487/04
-
公开(公告)号:JP2006522118A
公开(公告)日:2006-09-28
申请号:JP2006508007
申请日:2004-04-06
发明人: アニル・ペイテル , アンドリュー・デイビーズ , イアン・ミリチップ , ギャリー・パイロードー , スティーブン・トム , スティーブン・ブロー , ティモシー・ルーカー , トーマス・マッキナリー , ルクサナ・ラスル , ロジャー・ボナート
IPC分类号: C07C323/18 , A61K31/10 , A61K31/192 , A61K31/216 , A61K31/277 , A61K31/343 , A61K31/36 , A61K31/381 , A61K31/397 , A61K31/40 , A61K31/426 , A61K31/4418 , A61K31/47 , A61K31/495 , A61K31/505 , A61K31/506 , A61K31/5375 , A61K31/5377 , A61P1/00 , A61P1/04 , A61P1/16 , A61P3/10 , A61P5/14 , A61P7/02 , A61P7/04 , A61P9/00 , A61P9/08 , A61P9/10 , A61P9/12 , A61P11/00 , A61P11/06 , A61P11/08 , A61P11/14 , A61P13/02 , A61P13/08 , A61P13/10 , A61P13/12 , A61P15/10 , A61P17/00 , A61P17/02 , A61P17/04 , A61P17/06 , A61P17/14 , A61P19/02 , A61P21/04 , A61P25/00 , A61P25/02 , A61P25/14 , A61P25/28 , A61P27/02 , A61P27/16 , A61P29/00 , A61P31/08 , A61P31/12 , A61P31/16 , A61P31/18 , A61P35/00 , A61P35/02 , A61P37/02 , A61P37/04 , A61P37/06 , A61P37/08 , A61P43/00 , C07C59/48 , C07C59/68 , C07C59/70 , C07C65/24 , C07C69/92 , C07C69/94 , C07C205/35 , C07C205/37 , C07C217/80 , C07C235/42 , C07C255/54 , C07C255/55 , C07C271/28 , C07C275/32 , C07C311/29 , C07C317/22 , C07C317/28 , C07D205/04 , C07D207/02 , C07D213/30 , C07D213/61 , C07D213/71 , C07D213/72 , C07D213/73 , C07D213/76 , C07D215/12 , C07D215/14 , C07D215/18 , C07D233/52 , C07D239/24 , C07D239/26 , C07D239/34 , C07D239/42 , C07D239/52 , C07D277/20 , C07D277/52 , C07D285/10 , C07D295/10 , C07D295/192 , C07D295/22 , C07D295/26 , C07D307/80 , C07D317/54 , C07D333/56 , C07D403/04 , C07D417/04
CPC分类号: C07C59/68 , C07C59/70 , C07C65/24 , C07C69/94 , C07C205/35 , C07C205/37 , C07C217/80 , C07C235/42 , C07C255/55 , C07C271/28 , C07C275/32 , C07C311/29 , C07C317/22 , C07C323/18 , C07C2601/02 , C07D205/04 , C07D207/02 , C07D213/61 , C07D213/72 , C07D215/12 , C07D233/52 , C07D239/26 , C07D239/34 , C07D239/42 , C07D277/52 , C07D285/10 , C07D295/192 , C07D295/26 , C07D307/80 , C07D317/54 , C07D333/56 , C07D403/04 , C07D417/04
摘要: 本発明は、呼吸器疾患を処置するための有用な薬学的化合物としての式(I):
【化1】
の置換フェノキシ酢酸、それらを含む医薬組成物、およびその製造方法に関する。
-
-
-
-
-
-
-
-
-